Australia's Incannex rises on approval to start phase 1 clinical trial
21/07/2022 03:18
** ASX-listed shares of pharmaceutical development co
Incannex Healthcare IHL.AX climb as much as 9.5% to A$0.230,
their highest since July 11
** Co receives https://www.asx.com.au/asxpdf/20220721/pdf/45c17rz8v741h0.pdf
approval for a phase 1 clinical trial to investigate its
proprietary multi-use, anti-inflammatory drug IHL-675A
** Formulation and manufacturing of IHL-675A soft gel
capsules for the clinical trial has been completed; long-term
stability studies are ongoing, says IHL
** Co adds patient recruitment is scheduled to start in
August
** IHL's Australian shares down ~66.4% YTD, as of last close
(Reporting by Upasana Singh in Bengaluru)
((Upasana.Singh@thomsonreuters.com))
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed